Pancreatic endocrine tumours: Mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 127-134

  Corbo, V ^a   Beghelli, S ^a   Bersani, S ^a   Antonello, D ^a   Talamini, G ^a   Brunelli, M ^a   Capelli, P ^a   Falconi, M ^a   Scarpa, A ^a  

^a UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

Author keywords

Carcinoma; Endocrine; Kinases; Pancreas; Therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B BETA; PROTEIN KINASE LKB1; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR 1;

ARTICLE; ATTENUATION; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; EGFR GENE; FGFR3 GENE; FLT1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HER2 GENE; HETEROZYGOSITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIT GENE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; ONCOGENE; PANCREAS ISLET CELL TUMOR; PDGFRALPHA GENE; PIK3CA GENE; PRIORITY JOURNAL; RTK GENE; SOMATIC MUTATION; VEGFR1 GENE;

EID: 84855170001     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr048     Document Type: Article

References (60)

1. Antonello D, Gobbo S, Corbo V et al. Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma. Pancreatology 2009; 9: 25-33.
2. Capelli P, Martignoni G, Pedica F et al. Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med 2009; 133: 350-364.
3. Corbo V, Dalai I, Scardoni M et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 2010; 17: 771-783.
4. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014: 13-27.
5. Bettini R, Mantovani W, Boninsegna L et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009; 41: 49-55.
6. Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007; 14: 942-953.
7. Leary A, Johnston SR. Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest 2007; 25: 347-365.
8. Fabbro D, Ruetz S, Buchdunger E et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002; 93: 79-98.
9. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
10. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
11. Manning G, Whyte DB, Martinez R et al. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
12. Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol 2001; 54: 512-516.
13. Duran I, Salazar R, Casanovas O et al. New drug development in digestive neuroendocrine tumors. Ann Oncol 2007; 18: 1307-1313.
14. Grozinsky-Glasberg S, Franchi G, Teng M et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the AktmTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 2008; 87: 168-181.
15. Moreno A, Akcakanat A, Munsell MF et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008; 15: 257-266.
16. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007; 16: 219-224.
17. Missiaglia E, Dalai I, Barbi S et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28: 245-255.
18. Bardelli A, Parsons DW, Silliman N et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300: 949.
19. Davies H, Hunter C, Smith R et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005; 65: 7591-7595.
20. Stephens P, Edkins S, Davies H et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005; 37: 590-592.
21. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351.
22. Tokunaga E, Oki E, Nishida K et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 2006; 11: 199-208.
23. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
24. Hirsch F, Varella-Garcia M, Cappuzzo F et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-smallcell lung cancer patients treated with gefitinib. Ann Oncol 2007; 18: 752-760.
25. John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009; 28 (Suppl 1): S14-S23.
26. Shepherd FA, Tsao MS. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006; 24: 1219-1220; author reply 1220-1211.
27. Peghini PL, Iwamoto M, Raffeld M et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002; 8: 2273-2285.
28. Proca DM, Frankel WL. Pancreatic endocrine tumors-c-erb B2 (Her-2/neu), bcl-2, and p-53 immunohistochemical testing and their value in assessing prognosis. Appl Immunohistochem Mol Morphol 2008; 16: 44-47.
29. Papouchado B, Erickson LA, Rohlinger AL et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18: 1329-1335.
30. Fjallskog ML, Lejonklou MH, Oberg KE et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003; 9: 1469-1473.
31. Bergmann F, Breinig M, Hopfner M et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 2009; 104: 171-181.
32. Srivastava A, Alexander J, Lomakin I, Dayal Y. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors. Hum Pathol 2001; 32: 1184-1189.
33. Zhang L, Smyrk TC, Oliveira AM et al. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol 2009; 33: 1562-1569.
34. Goebel SU, Iwamoto M, Raffeld M et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 2002; 62: 3702-3710.
35. Chaudhry A, Papanicolaou V, Oberg K et al. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992; 52: 1006-1012.
36. Capurso G, Lattimore S, Crnogorac-Jurcevic T et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 2006; 13: 541-558.
37. Cecconi D, Donadelli M, Rinalducci S et al. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics 2007; 7: 1644-1653.
38. Corbo V, Ritelli R, Barbi S et al. Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. PLoS One 2010; 5: e12653.
39. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
40. Brunelli M, Eble JN, Zhang S et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol 2005; 18: 161-169.
41. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-168.
42. Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxiatelangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38: 873-875.
43. Pauls K, Merkelbach-Bruse S, Thal D et al. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology 2005; 46: 166-175.
44. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
45. Ikenoue T, Kanai F, Hikiba Y et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562-4567.
46. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 2006; 103: 1475-1479.
47. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61: 3541-3543.
48. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999; 98: 641-650.
49. Lee JW, Soung YH, Kim SY et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24: 1477-1480.
50. Samuels Y, Diaz LA Jr., Schmidt-Kittler O et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7: 561-573.
51. Moore PS, Missiaglia E, Antonello D et al. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 2001; 32: 177-181.
52. Rindi G, Bordi C. Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 2005; 19: 519-534.
53. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
54. Zamo A, Bertolaso A, Franceschetti I et al. Microfluidic deletion/insertion analysis for rapid screening of KIT and PDGFRA mutations in CD117-positive gastrointestinal stromal tumors: diagnostic applications and report of a new KIT mutation. J Mol Diagn 2007; 9: 151-157.
55. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
56. Yao JC, Zhang JX, Rashid A et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007; 13: 234-240.
57. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
58. von Wichert G, Jehle PM, Hoeflich A et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60: 4573-4581.
59. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
60. Eriksson A, Siegbahn A, Westermark B et al. PDGF alpha- and beta-receptors activate unique and common signal transduction pathways. Embo J 1992; 11: 543-550.